0743 GMT - Novo Nordisk's CEO departure suggests another profit warning is highly possible, Intron Health's Naresh Chouhan and Dominic Rose say in a research note. Consensus estimates for sales of the Danish pharma giant's Ozempic diabetes drug this year look too high, as new prescriptions have now turned negative, the analysts say. Meanwhile, Intron's expectations that sales of the Wegovy obesity drug will reach an inflection point thanks to a deal with CVS Health and the anticipated end of sales of compounded versions is likely a best-case scenario, the analysts say. "Furthermore, following Friday's CEO news, we believe there is further risk to 2025 guidance," Intron says. Novo Nordisk earlier this month cut its full-year guidance and on Friday said CEO Lars Fruergaard Jorgensen would leave the company. Shares rise 1.9%. (adria.calatayud@wsj.com)
(END) Dow Jones Newswires
May 20, 2025 03:43 ET (07:43 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。